LOG IN/REGISTER >
FORWARD TO A COLLEAGUE >
INDICATION/SAFETY INFORMATION >

Modular comprehensive slide presentation

Modular slide presentationThis comprehensive slide presentation by Genentech provides more information on the pathophysiology of acute ischemic stroke and the clinical pharmacology of Activase (t-PA).

More specifically, the clinical stroke slide kit:

  • Reviews stroke epidemiologic data and basic brain anatomy
  • Describes diagnosis and evaluation of acute ischemic stroke, including:
    • – Utilization of such well-known stroke assessment scales as the National Institutes of Health Stroke Scale (NIHSS)
    • – Outlines of the latest telestroke strategies with supporting information and resources
    • – Use of advanced diagnostic imaging techniques, including magnetic resonance imaging (MRI) and CT scans
  • Discusses guidelines for treating acute ischemic stroke
  • Demonstrates the clinical evidence of thrombolytic efficacy and safety with Activase (t-PA), including findings from the pivotal National Institute of Neurological Disorders and Stroke (NINDS) clinical study and several postapproval studies
  • Highlights strategies for potentially improving the outcomes of acute ischemic stroke patients, including:
    • – Protocol adherence
    • – Patient selection
    • – Coordinated stroke care and system organization
  • Presents the proper dosing, reconstitution, and administration of Activase (t-PA)
  • Outlines the latest telestroke strategies with supporting information and resources

Slide presentations are available in 9 separate modules

  1. Stroke basics
  2. Prehospital management
  3. In-hospital evaluation and treatment
  4. Dosing and administration and post treatment care
  5. Clinical data
  6. Stroke centers
  7. Telestroke
  8. Myths and facts
  9. Indication and important safety information for Activase (t-PA)
DOWNLOAD



Indication
Activase (Alteplase) is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS).

Important Safety Information
Activase therapy in patients with AIS is contraindicated in certain situations (eg, suspicion of subarachnoid hemorrhage on pretreatment evaluation, recent (within 3 months) intracranial or intraspinal surgery, history of intracranial hemorrhage, uncontrolled hypertension at time of treatment, active internal bleeding, known bleeding diathesis (eg, current use of oral anticoagulants, administration of heparin within 48 hours of onset of stroke, platelet count <100,000) (see CONTRAINDICATIONS for full list).

The most common complication during Activase therapy is bleeding. Should serious bleeding in a critical location (intracranial, gastrointestinal, retroperitoneal, pericardial) occur, Activase therapy should be discontinued immediately. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

The risks of Activase therapy may be increased and should be weighed against the anticipated benefits in certain conditions. [See WARNINGS in full prescribing information].

  • Patients with severe neurological deficit (eg, NIHSS >22) at presentation. There is an increased risk of intracranial hemorrhage in these patients.
  • Patients with major early infarct signs on a computerized cranial tomography (CT) scan (eg, substantial edema, mass effect, or midline shift).

Treatment of patients with minor neurological deficit or with rapidly improving symptoms is not recommended.

Orolingual angioedema has been observed in postmarketing experience in patients treated with Activase for AIS. Patients should be monitored during and for several hours after infusion for signs of orolingual angioedema.

Please click here for full prescribing information.